News & Media
Diplomat Opens Facility in Arizona
FLINT, Mich. — Sept. 27, 2018 — Diplomat Pharmacy, Inc. (NYSE: DPLO), has opened a 75,000-square-foot facility in Chandler, Arizona, to bolster pharmacy operations and ensure business continuity.
Diplomat expects the location to create 200 local jobs over the next year. Many positions are posted online at diplomatpharmacy.com/careers.
CEO and Chairman Brian Griffin said the Chandler facility — 485 N. Juniper Drive — increases Diplomat’s capacity to serve more patients with greater efficiency. It will feature operational capabilities redundant to those at Diplomat’s other pharmacies nationwide, including call center services and dispensing.
Griffin called the expansion a significant step forward. He said expanding Diplomat’s operations, technology, and personnel will help ensure the company can always provide uninterrupted service to patients and partners across the U.S.
“Our patients face complex and chronic health conditions. It is our duty to serve those patients and guarantee their timely access to critical medications,” Griffin said. “This addition reflects our investment in doing what’s best and right for our patients.”
Griffin said the move reflects Diplomat’s strategy to provide a scalable platform to meet growing demand for customized services throughout healthcare.
“As patient services become a competitive driver for the industry, Diplomat’s service model is primed to meet the market demand,” he said. “This new space will allow us to provide the best service more intelligently and efficiently to providers, manufacturers, and payers — ultimately to deliver better care to patients.”
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give current expectations or forecasts of future events or our future financial or operating performance, and include Diplomat’s expectations regarding the CEO search process. The forward-looking statements contained in this press release are based on management’s good-faith belief and reasonable judgment based on current information. These statements are qualified by important risks and uncertainties, many of which are beyond our control, which could cause our actual results to differ materially from those forecasted or indicated by such forward-looking statements. These risks and uncertainties include CEO succession planning and the dependence on our senior management and key employees, and the additional factors set forth in “Risk Factors” in Diplomat’s Annual Report on Form 10-K for the year ended Dec. 31, 2017, and in subsequent reports filed with or furnished to the Securities and Exchange Commission. Except as may be required by any applicable laws, Diplomat assumes no obligation to publicly update such forward-looking statements, which are made as of the date hereof or the earlier date specified herein, whether as a result of new information, future developments, or otherwise.
Diplomat (NYSE: DPLO) is the nation’s largest independent provider of specialty pharmacy and infusion services. Diplomat helps people with complex and chronic health conditions in all 50 states, partnering with payers, providers, hospitals, manufacturers, and more. Rooted in this patient care expertise, Diplomat also serves payers through CastiaRx, a leading specialty benefit manager, and offers tailored solutions for healthcare innovators through EnvoyHealth. Diplomat opened its doors in 1975 as a neighborhood pharmacy with one essential tenet: “Take good care of patients and the rest falls into place.” Today, that tradition continues — always focused on improving patient care. For more information, visit diplomat.is.
Corporate Communications Manager
810.768.9871 | email@example.com